A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer

BJU International

Volumn 104, Issue 2, 2009, Pages 184-188

  Gazzaniga, Paola ^a,b   Gradilone, Angela ^a   De Berardinis, Ettore ^b   Sciarra, Alessandro ^b   Cristini, Cristiano ^b   Naso, Giuseppe ^a   Di Silverio, Franco ^b   Frati, Luigi ^a   Aglianò, Anna Maria ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chemosensitivity test; Drug resistance; Intravesical therapy; Non muscle invasive bladder cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BCG VACCINE; GEMCITABINE; MITOMYCIN C;

ARTICLE; BLADDER CANCER; CANCER RISK; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; TRANSURETHRAL RESECTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCG VACCINE; COHORT STUDIES; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; URINARY BLADDER NEOPLASMS;

EID: 67650647141     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08342.x     Document Type: Article

References (14)

1. Barocas DA, Clark PE. Bladder cancer. Curr Opin Oncol 2008 20 : 307 14
2. Sánchez-Carbayo M, Cordon-Cardó C. Molecular alterations associated with bladder cancer progression. Semin Oncol 2007 34 : 75 84 (Pubitemid 46436122)
3. Karam JA, Lotan Y, Karakiewicz PI et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007 8 : 128 36
4. Gazzaniga P, Silvestri I, Gradilone A, Aglianò AM. Re: the increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int 2008 101 : 127 (Pubitemid 350233577)
5. Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JL. Intravesical treatments of bladder cancer: review. Pharm Res 2008 25 : 1500 10
6. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 2004 1 : 27 42
7. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 2004 95 : 753 7
8. Chen F, Zhang G, Iwamoto Y, See WA. Bacillus Calmette-Guerin initiates intracellular signaling in a transitional carcinoma cell line by cross-linking α5β1 integrin. J Urol 2003 170 : 605 10
9. Babjuk M, Oosterlinck W, Sylvester R et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008 54 : 303 14
10. Gazzaniga P, Gradilone A, Vercillo R et al. Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Int J Cancer 1996 69 : 100 4
11. Gazzaniga P, Gradilone A, Naso G et al. Chemoresistance profile of circulating tumor cells: toward a clinical benefit? Int J Cancer 2008 123 : 1730 2
12. Hendricksen K, Witjes JA. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer. Curr Opin Urol 2007 17 : 352 7
13. Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. J Urol 2007 177 : 1727 31
14. Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 2007 61 : 299 305 (Pubitemid 47189735)